Barbara Alice Weber

US Patent:

58374922, Nov 17, 1998

Filed:

Apr 29, 1996

Appl. No.:

8/639501

Inventors:

Sean V. Tavtigian - Salt Lake City UT
Alexander Kamb - Salt Lake City UT
Jacques Simard - St. Augustin de Desmuures, CA
Fergus Couch - St. Davids PA
Johanna M. Rommens - Toronto, CA
Barbara L. Weber - Merion PA

Assignee:

Myriad Genetics, Inc. - Salt Lake City UT
Endo Recherche, Inc. - Sainte-Foy
HSC Research & Development Limited Partnership - Toronto
Trustees of the University of Pennsylvaina - Philadelphia PA

International Classification:

C12N 1563
C12N 1579
C12N 1509
C12N 510

US Classification:

435 691

Abstract:

The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect a human breast cancer predisposing gene (BRCA2), some mutant alleles of which cause susceptibility to cancer, in particular breast cancer. More specifically, the invention relates to germline mutations in the BRCA2 gene and their use in the diagnosis of predisposition to breast cancer. The present invention further relates to somatic mutations in the BRCA2 gene in human breast cancer and their use in the diagnosis and prognosis of human breast cancer. Additionally, the invention relates to somatic mutations in the BRCA2 gene in other human cancers and their use in the diagnosis and prognosis of human cancers. The invention also relates to the therapy of human cancers which have a mutation in the BRCA2 gene, including gene therapy, protein replacement therapy and protein mimetics. The invention further relates to the screening of drugs for cancer therapy.

US Patent:

61241040, Sep 26, 2000

Filed:

Mar 20, 1998

Appl. No.:

9/044908

Inventors:

Sean V. Tavtigian - Salt Lake City UT
Alexander Kamb - Salt Lake City UT
Jacques Simard - St. Augustin de Desmuures, CA
Fergus Couch - St. Davids PA
Johanna M. Rommens - Toronto, CA
Barbara L. Weber - Merion PA

Assignee:

Myriad Genectics, Inc. - Salt Lake City UT
Endo Recherche, Inc. - Sainte-Foy
HSC Reseach & Development Limited Partnership - Toronto
Trustees of the University of Pennsylvania - Philadelphia PA

International Classification:

C12N 1509
C12N 508

US Classification:

435 72

Abstract:

The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect a human breast cancer predisposing gene (BRCA2), some mutant alleles of which cause susceptibility to cancer, in particular breast cancer. More specifically, the invention relates to germline mutations in the BRCA2 gene and their use in the diagnosis of predisposition to breast cancer. The present invention further relates to somatic mutations in the BRCA2 gene in human breast cancer and their use in the diagnosis and prognosis of human breast cancer. Additionally, the invention relates to somatic mutations in the BRCA2 gene in other human cancers and their use in the diagnosis and prognosis of human cancers. The invention also relates to the therapy of human cancers which have a mutation in the BRCA2 gene, including gene therapy, protein replacement therapy and protein mimetics. The invention further relates to the screening of drugs for cancer therapy.

US Patent:

60338571, Mar 7, 2000

Filed:

Mar 20, 1998

Appl. No.:

9/044946

Inventors:

Sean V. Tavtigian - Salt Lake City UT
Alexander Kamb - Salt Lake City UT
Jacques Simard - St. Augustin de Desmuures, CA
Fergus Couch - St. Davids PA
Johanna M. Rommens - Toronto, CA
Barbara L. Weber - Merion PA

Assignee:

Myriad Genetics, Inc. - Salt Lake City UT
Endo Recherche, Inc.
HSC Research & Development Limited Parntership
Trustees of the Univ. of Pennsylvania - Philadelphia PA

International Classification:

C07H 2100
C12N 1563
C12N 1579
C12N 1511
C12N 1509

US Classification:

435 6

Abstract:

The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect a human breast cancer predisposing gene (BRCA2), some mutant alleles of which cause susceptibility to cancer, in particular breast cancer. More specifically, the invention relates to germline mutations in the BRCA2 gene and their use in the diagnosis of predisposition to breast cancer. The present invention further relates to somatic mutations in the BRCA2 gene in human breast cancer and their use in the diagnosis and prognosis of human breast cancer. Additionally, the invention relates to somatic mutations in the BRCA2 gene in other human cancers and their use in the diagnosis and prognosis of human cancers. The invention also relates to the therapy of human cancers which have a mutation in the BRCA2 gene, including gene therapy, protein replacement therapy and protein mimetics. The invention further relates to the screening of drugs for cancer therapy.